CELZ 8-K: CEO $100,000 and CFO $25,000 bonuses approved by board

Creative Medical Technology Holdings (CELZ) reported a compensation action.

Accepted by SEC EDGAR 11/12/2025 - 06:12 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Creative Medical Technology Holdings (CELZ) reported a compensation action. On November 6, 2025, the Board’s Compensation Committee approved bonuses of $100,000 for CEO Timothy Warbington and $25,000 for CFO Donald Dickerson.

The company also noted its common stock trades on Nasdaq under CELZ. An Exhibit 104 cover page interactive data file was included.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CELZ disclose in its 8-K?

The Compensation Committee approved executive bonuses for the CEO and CFO.

How much were the executive bonuses at CELZ?

The CEO was awarded $100,000 and the CFO $25,000.

When were the bonuses approved by CELZ?

The approvals occurred on November 6, 2025.

Which officers at CELZ received bonuses?

CEO Timothy Warbington and CFO Donald Dickerson.

Where is CELZ listed and under what ticker?

CELZ common stock trades on the Nasdaq under ticker CELZ.

What exhibit accompanied the CELZ 8-K?

Exhibit 104: Cover Page Interactive Data File (Inline XBRL).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001187953false00011879532025-11-062025-11-06iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

Creative Medical Technology Holdings, Inc.

(Exact name of registrant as specified in its charter)

Nevada		000-53500		87-0622284
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

211 E Osborn Road, Phoenix, AZ 85012

(Address of principal executive offices)

(480) 399-2822

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	CELZ	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 6, 2025, the Compensation Committee of the Board of Directors of Creative Medical Technology Holdings, Inc. (the “Company”) approved the payment of bonuses to Timothy Warbington, the Company’s Chief Executive Officer, and Donald Dickerson, the Company’s Chief Financial Officer, in the amounts of $100,000 and $25,000, respectively.

Item 9.01 Financial Statements and Exhibits.

(d)	Exhibits.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Creative Medical Technology Holdings, Inc.
Date: November 12, 2025	By:	/s/ Timothy Warbington
		Timothy Warbington, Chief Executive Officer

3